Duplication of a chromosome 2 segment in production CHO cell lines correlates with age‐related growth improvement

Author:

Wei Wei1ORCID,Zielewicz Laura1,Zhang Lin12

Affiliation:

1. Cell Line Development Biotherapeutics Pharmaceutical Sciences, Pfizer Inc Andover Massachusetts USA

2. Bioprocess Research and Development Merck & Co. Inc. Kenilworth New Jersey USA

Abstract

AbstractMonitoring the stability of recombinant Chinese Hamster Ovary (CHO) cell lines is essential to ensure the selection of production cell lines suitable for biomanufacturing. It has been frequently observed that recombinant CHO cell lines develop phenotypic changes upon aging, such as accelerated cell growth in late generation cultures. However, the mechanism responsible for age‐correlated changes is poorly understood. In this study, we investigated the molecular mechanisms underlying the age‐correlated cell growth improvement in Pfizer's platform fed‐batch production process, by examining multiple cell lines derived from different CHO expression systems, expressing a variety of monoclonal antibodies (mAbs). Comprehensive whole‐genome resequencing analysis revealed duplication of a continuous 50.2 Mbp segment in chromosome 2 (Chr2) specific to clones that showed age‐correlated growth change as compared to clones that did not exhibit age‐correlated growth change. Moreover, such age‐ and growth‐related Chr2 duplication was independent of the presence or type of recombinant monoclonal antibody expression. When we compared transcriptome profiles from low‐growth and high‐growth cell lines, we found that >95% of the genes overexpressed in high‐growth cell lines were in the duplicated Chr2 segment. To the best of our knowledge, this is the first report of large genomic duplication, specific to Chr2, being associated with age‐correlated growth change. Investigation of the cause‐and‐effect relationship between the genes identified in the duplicated regions and age‐correlated growth change is underway. We are confident that this effort will lead to improved cell line screening and targeted rational cell line engineering efforts to develop cell lines with improved stability performance.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3